The Synthetic Microneurotrophin BNN27 Affects Retinal Function in Rats With Streptozotocin-Induced Diabetes

Authors:

Abstract
BNN27, a C17-spiroepoxy derivative of DHEA, was shown to have anti-apoptotic properties via mechanisms involving the NGF receptors (TrkA/ p75NTR). In this study we examined the effects of BNN27 on neural/glial cell function, apoptosis and inflammation in the experimental rat streptozotocin (STZ)-model of diabetic retinopathy (DR). The ability of BNN27 to activate the TrkA receptor and regulate p75NTR expression was investigated. BNN27 (2,10,50mg/kg,7days,i.p.) administration four weeks post STZ-injection (Paradigm A) reversed the diabetes-induced glial activation, loss of function of amacrine cells (bNOS/TH expression) and ganglion cell axons via a TrkAR-dependent mechanism. BNN27 activated/phosphorylated the TrkAY490 residue in the absence but not the presence of TrkAR inhibitor and abolished the diabetes-induced increase in p75NTR expression. However, it had no effect on retinal cell death (TUNEL+ cells). A similar result was observed when BNN27(10mg/kg,i.p.) was administered at the onset of diabetes, every other day for four weeks (Paradigm B). However, BNN27 decreased the activation of caspase-3 in both paradigms. Finally, BNN27 reduced the pro-inflammatory (TNFα,IL1β) and increased the anti-inflammatory (IL-10,IL-4) cytokine levels. These findings suggest that BNN27 has the pharmacological profile of a therapeutic for diabetic retinopathy, since it targets both the neurodegenerative and inflammatory components of the disease.
Funding Information
  • ARISTEIA II (European Social Fund-ESF)

This publication has 45 references indexed in Scilit: